Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

DIAMANTE Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles

Coordinator
Diamante Societa Benefit S.r.l, Italy
Runs
1 January 2025 to 31 December 2026
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101189019

What the project is doing

In the project's own words, from its summary on CORDIS.

At Diamante Società Benefit srl we leverage our proprietary Plant Molecular Farming Platform to develop cutting-edge treatments for autoimmune diseases through virus nanoparticles (VNP). Our patented protected VNPs’ mode of action is based on Antigen Specific Immunotehrapy. This means that our VNPs are able to re-educate the immune system to immune tolerate the specific body’s own cell (autoantigen) causing the disease.

Our Proof-of-concept studies in Rheumatoid Arthritis (RA - our first indication) animal models have shown complete remission of arthritic symptoms. Currently, there is no cure or preventive measure for this chronic condition; first-line treatments revolve around immunosuppression, causing several side effects. Our drug will be the first treatment based on the restoration of self-tolerance, while maintaining the immune system’s ability to defend itself; hence reducing potential harmful side effects.

We are now seeking funding to cover the next clinical development steps.

Topics

Who is involved

OrganisationCityCountryRole
Diamante Societa Benefit S.r.lVeronaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI